Lilly's psoriatic arthritis drug succeeds in late-stage study – Reuters
Lilly's psoriatic arthritis drug succeeds in late-stage studyReutersEli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients more than a placebo did in a late-stage trial. Up to 30 percent of psoriasis patients develop psoriatic arthritis, an …Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the …PR Newswire (press release)all 25 news articles »
[monetize id=”1″]
[monetize id=”2″]
